newsfilter
← Latest News
PR Newswire·

Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders

CRDL
  • Cardiol Therapeutics Inc. held its Annual General Meeting virtually on June 24, 2026, where shareholders approved all management resolutions.
  • The company elected eight directors for the ensuing year: Dr. Guillermo Torre-Amione, David Elsley, Chris Waddick, Teri Loxam, Dr. Timothy Garnett, Jennifer Chao, Peter Pekos, & Colin Stott.
  • BDO Canada LLP was appointed as the company's auditor for the next fiscal year, with directors authorized to set their remuneration.
  • Director election votes received between 96.24% & 99.19% support from shareholders.
  • A webcast of the meeting is available in the Investors section of the Cardiol website.
  • The company's lead candidate, CardiolRx™, is being evaluated in the MAVERIC Program for recurrent pericarditis, which includes a completed Phase II study & an ongoing pivotal Phase III trial.
  • The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for pericarditis treatment.
  • The ARCHER Program completed a Phase II study of CardiolRx™ for acute myocarditis.
  • Cardiol is developing CRD-38, a subcutaneous formulation for inflammatory heart disease, including heart failure.